. Recommandation-pour-la-pratique-clinique, Prise en charge de la BPCO Mise à jour, Rev Mal Respir, vol.27, pp.522-570, 2009.

D. Donnell, S. Aaron, J. Bourbeau, P. Hernandez, D. Marciniuk et al., Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010 Available from: http://www.goldcopd.org, 2011.

J. Piquet, Caract??ristiques et prise en charge des exacerbations aigu??s de BPCO hospitalis??es. ??tude EABPCO???CPHG du Coll??ge des pneumologues des h??pitaux g??n??raux, Revue des Maladies Respiratoires, vol.27, issue.1, pp.19-29, 2010.
DOI : 10.1016/j.rmr.2009.11.007

G. Donaldson, T. Seemungal, A. Bhowmik, and J. Wedzicha, Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease, Thorax, vol.57, issue.10, pp.847-52, 2002.
DOI : 10.1136/thorax.57.10.847

J. Soler, M. Arcia, M. , R. Sanchhez, P. Salceo et al., Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease, Thorax, vol.60, issue.11, pp.925-956, 2005.
DOI : 10.1136/thx.2005.040527

G. Donaldson and J. Wedzicha, COPD exacerbations {middle dot} 1: Epidemiology, Thorax, vol.61, issue.2, pp.164-172, 2006.
DOI : 10.1136/thx.2005.041806

J. Hurst, J. Vestbo, A. Anzueto, N. Locantore, H. Müllerova et al., Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease, New England Journal of Medicine, vol.363, issue.12, pp.1128-1166, 2010.
DOI : 10.1056/NEJMoa0909883

R. Halbert, J. Natoli, and A. Gano, Global burden of COPD: systematic review and meta-analysis, European Respiratory Journal, vol.28, issue.3, pp.523-532, 2006.
DOI : 10.1183/09031936.06.00124605

C. Rycroft, . Heyes, and . Lanza, Epidemiology of chronic obstructive pulmonary disease: a literature review, International Journal of Chronic Obstructive Pulmonary Disease, vol.7, pp.457-94, 2012.
DOI : 10.2147/COPD.S32330

A. Buist, M. Mcburnie, and W. Vollmer, International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study, The Lancet, vol.370, issue.9589, pp.741-750, 2007.
DOI : 10.1016/S0140-6736(07)61377-4

A. Menezes, R. Perez-padilla, and J. Jardim, Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study, The Lancet, vol.366, issue.9500, pp.1875-1881, 2005.
DOI : 10.1016/S0140-6736(05)67632-5

D. Marco, R. Accordini, S. Cerveri, and I. , An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages, Thorax, vol.59, issue.2, pp.120-125, 2004.
DOI : 10.1136/thorax.2003.011163

C. Furhrman and M. Delmas, ??pid??miologie descriptive de la bronchopneumopathie chronique obstructive (BPCO) en France, Revue des Maladies Respiratoires, vol.27, issue.2, pp.160-168, 2010.
DOI : 10.1016/j.rmr.2009.08.003

C. Fuhrman, M. Delmas, J. Nicolou, and E. Jougla, Mortalité liée à la BPCO en France métropolitaine entre, BEH thématique, pp.27-35, 2003.

. Thun, 50-Year Trends in Smoking-Related Mortality in the United States, New England Journal of Medicine, vol.368, issue.4, pp.351-64, 2013.
DOI : 10.1056/NEJMsa1211127

C. Murray and A. Lopez, Alternative projections of mortality and disability by cause 1990???2020: Global Burden of Disease Study, The Lancet, vol.349, issue.9064, pp.1498-1504, 1997.
DOI : 10.1016/S0140-6736(96)07492-2

R. Pauwels and R. , Burden and clinical features of chronic obstructive pulmonary disease (COPD), The Lancet, vol.364, issue.9434, pp.613-620, 2004.
DOI : 10.1016/S0140-6736(04)16855-4

M. Fournier, A. Tonnel, and B. Housset, Impact ??conomique de la BPCO en France : ??tude SCOPE, Revue des Maladies Respiratoires, vol.22, issue.2, pp.247-55, 2005.
DOI : 10.1016/S0761-8425(05)85478-6

S. Salvi and P. Barnes, Chronic obstructive pulmonary disease in non-smokers, The Lancet, vol.374, issue.9691, pp.733-743
DOI : 10.1016/S0140-6736(09)61303-9

M. Ezzati and D. Kammen, Indoor air pollution from biomass combustion and acute respiratory infections in Kenya: an exposure-response study, The Lancet, vol.358, issue.9282, pp.619-624, 2001.
DOI : 10.1016/S0140-6736(01)05777-4

S. Liu, Y. Zhou, and X. Wang, Biomass fuels are the probable risk factor for chronic obstructive pulmonary disease in rural South China, Thorax, vol.62, issue.10, pp.889-897, 2007.
DOI : 10.1136/thx.2006.061457

N. Molfino, Genetics of COPD, Chest, vol.125, issue.5, pp.1929-1940, 2004.
DOI : 10.1378/chest.125.5.1929

I. Blanco, F. De-serres, and E. Fernandez-bustillo, Estimated numbers and prevalence of PI*S and PI*Z alleles of ??1-antitrypsin deficiency in European countries, European Respiratory Journal, vol.27, issue.1, pp.77-84, 2006.
DOI : 10.1183/09031936.06.00062305

J. Stoller and L. Aboussouan, ??1-antitrypsin deficiency, The Lancet, vol.365, issue.9478, pp.2225-2236, 2005.
DOI : 10.1016/S0140-6736(05)66781-5

M. Charlson, R. Charlson, W. Briggs, and J. Hollenberg, Can Disease Management Target Patients Most Likely to Generate High Costs? The Impact of Comorbidity, Journal of General Internal Medicine, vol.39, issue.11, pp.464-473, 2007.
DOI : 10.1007/s11606-007-0130-7

D. Mannino, D. Thorn, A. Swensen, and F. Holguin, Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD, European Respiratory Journal, vol.32, issue.4, pp.962-969, 2008.
DOI : 10.1183/09031936.00012408

. Initiatives and . Bpco-scientic-committee, Clinical COPD phenotypes: a novel approach using principal component and cluster analyses, Eur Respir J, vol.36, pp.531-540, 2010.

M. Han, G. Washko, M. Dransfield, L. Liu, N. Marchetti et al., CT phenotype correlates with health status and BODE in COPD, Eur Respir J, vol.36, pp.5551-5585, 2010.

G. Gayan-ramirez, W. Janssens, M. Decramer, and D. , Physiopathologie de la bronchopneumopathie chronique obstructive, EMC - Pneumologie, vol.9, issue.1, pp.1-12
DOI : 10.1016/S1155-195X(12)70003-8

M. Decramer, W. Janssens, and M. Miravitlles, Chronic obstructive pulmonary disease, The Lancet, vol.379, issue.9823, pp.1341-51, 2012.
DOI : 10.1016/S0140-6736(11)60968-9

P. Barnes, Small Airways in COPD, New England Journal of Medicine, vol.350, issue.26, pp.2635-2637, 2004.
DOI : 10.1056/NEJMp048102

J. Hogg, F. Chu, S. Utokaparch, R. Woods, W. Elliott et al., The Nature of Small-Airway Obstruction in Chronic Obstructive Pulmonary Disease, New England Journal of Medicine, vol.350, issue.26, pp.2645-2653, 2004.
DOI : 10.1056/NEJMoa032158

C. Fletcher and R. Peto, The natural history of chronic airflow obstruction., BMJ, vol.1, issue.6077, pp.1645-1653, 1977.
DOI : 10.1136/bmj.1.6077.1645

N. Anthonisen, J. Connett, J. Kiley, M. Altose, W. Bailey et al., Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study, JAMA: The Journal of the American Medical Association, vol.272, issue.19, pp.1497-505, 1994.
DOI : 10.1001/jama.272.19.1497

P. Gros, A. Hermogenes, H. Sacks, J. Lau, and R. Levandowski, The Efficacy of Influenza Vaccine in Elderly Persons, Annals of Internal Medicine, vol.123, issue.7, pp.518-545, 1995.
DOI : 10.7326/0003-4819-123-7-199510010-00008

P. Wongsurakiat, K. Maranetra, and C. Wasi, Acute Respiratory Illness in Patients With COPD and the Effectiveness of Influenza Vaccination, Chest, vol.125, issue.6, pp.2011-2031, 2004.
DOI : 10.1378/chest.125.6.2011

N. Ambrosino and A. Simonds, The clinical management in extremely severe COPD, Respiratory Medicine, vol.101, issue.8, pp.1613-1624, 2007.
DOI : 10.1016/j.rmed.2007.02.011

F. Bart and B. Wallaert, Indications de la réhabilitation respiratoire chez le BPCO, Rev Mal Respir, vol.22, pp.7-17, 2005.

T. Troosters, R. Casaburi, R. Gosselink, and M. Decramer, Rehabilitation in chronic obstructive pulmonary disease, Am J Respir Crit Care Med, vol.172, pp.19-38, 2005.
DOI : 10.1183/1025448x.00038021

D. Tashkin, B. Celli, S. Senn, D. Burkhart, S. Kesten et al., A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease, New England Journal of Medicine, vol.359, issue.15, pp.1543-54, 2008.
DOI : 10.1056/NEJMoa0805800

J. Vestbo, R. Pauwels, J. Anderson, P. Jones, and P. Calverley, Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease, Thorax, vol.60, issue.4, pp.301-305, 2005.
DOI : 10.1136/thx.2004.025411

D. Donnell, F. Sciurba, B. Celli, D. Mahler, K. Webb et al., Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD, Eur Respir J Chest, vol.5130, issue.52, pp.659-64647, 1992.

N. Roche, Y. Martinat, J. Marcos, H. Pégliasco, and R. Scherrer, Prise en charge de la BPCO en pneumologie selon le stade de s??v??rit??, Revue des Maladies Respiratoires, vol.26, issue.9, pp.933-974, 2009.
DOI : 10.1016/S0761-8425(09)73328-5

D. Price, Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns, International Journal of Chronic Obstructive Pulmonary Disease, vol.2014, pp.9889-905
DOI : 10.2147/COPD.S62750

I. Wilson, Depression in the patient with COPD, International Journal of COPD, vol.1, issue.1, pp.61-64, 2006.
DOI : 10.2147/copd.2006.1.1.61

P. Hernandez, B. Ms, J. Bourbeau, C. Chan, . Marciniuk et al., Canadian Practice Assessment in Chronic Obstructive Pulmonary Disease: Respiratory Specialist Physician Perception Versus Patient Reality, Canadian Respiratory Journal, vol.20, issue.2, pp.97-105, 2013.
DOI : 10.1155/2013/369019

. Glaab, Guideline-based survey of outpatient COPD management by pulmonary specialists in Germany, International Journal of Chronic Obstructive Pulmonary Disease, vol.7, pp.101-108, 2012.
DOI : 10.2147/COPD.S27887

K. Fritsch, M. Jacot, A. Klarer, F. Wick, P. Bruggmann et al., Adherence to the Swiss quidelines for management of COPD : Experience of a Swiss teaching hospital, Swiss Med Wkly, vol.135, pp.116-137, 2005.

S. Suissa, V. Patenaude, F. Lapi, and P. Ernst, Inhaled corticosteroids in COPD and the risk of serious pneumonia, Thorax, vol.183, issue.(2), pp.1029-1036, 2013.
DOI : 10.1136/thoraxjnl-2012-202872

D. Price, Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD Prim, Care Respir J, vol.22, issue.1, pp.92-100, 2013.

M. Rudolf, The Reality of Drug Use in COPD, Chest, vol.117, issue.2, pp.29-32, 2000.
DOI : 10.1378/chest.117.2_suppl.29S

G. Salinas, J. Williamson, and R. Kalhan, Barriers to adherence to chronic obstructive pulmonary disease guidelines by primary care physicians, International Journal of Chronic Obstructive Pulmonary Disease, vol.6, pp.171-179, 2011.
DOI : 10.2147/COPD.S16396

J. Donohue, J. Van-noord, and E. Bateman, A 6-Month, Placebo-Controlled Study Comparing Lung Function and Health Status Changes in COPD Patients Treated With Tiotropium or Salmeterol, Chest, vol.122, issue.1, pp.47-55, 2002.
DOI : 10.1378/chest.122.1.47

J. Donohue, C. Kalberg, E. A. Merchant, K. Knobil, and K. , A Short-Term Comparison of Fluticasone Propionate/Salmeterol with Ipratropium Bromide/Albuterol for the Treatment of COPD, Treatments in Respiratory Medicine, vol.261, issue.22, pp.173-181, 2004.
DOI : 10.2165/00151829-200403030-00005

N. Roche, Qualit?? des soins dans le domaine de la BPCO, Revue des Maladies Respiratoires, vol.23, issue.3, pp.6-44, 2006.
DOI : 10.1016/S0761-8425(06)71587-X